Sign in
DRMA Stock Price, Chart, Stats & News
Dermata Therapeutics, Inc.
Save
Dermata Therapeutics, Inc. (DRMA) does not currently pay a dividend.
879,209
Market cap
–
Current P/E
–
Forward P/E
DRMA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -96.12% |
ROE | -130.89% |
D/E | – |
Interest coverage ratio | – |
DRMA valuation
P/E | – |
P/S | – |
P/B | 0.23x |
P/CF | -0.19x |
P/FCF | -0.10x |
P/OCF | -0.19x |
PEG | -0.00x |
EV multiple | -1.10x |
About
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea.
Similar securities
Based on sector and market capitalization
Report issue